BIOTE CORP -A (BTMD) Fundamental Analysis & Valuation

NASDAQ:BTMD • US0906831039

Current stock price

1.39 USD
+0 (+0.36%)
Last:

This BTMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. BTMD Profitability Analysis

1.1 Basic Checks

  • BTMD had positive earnings in the past year.
  • In the past year BTMD had a positive cash flow from operations.
  • Of the past 5 years BTMD 4 years were profitable.
  • Of the past 5 years BTMD 4 years had a positive operating cash flow.
BTMD Yearly Net Income VS EBIT VS OCF VS FCFBTMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M -60M

1.2 Ratios

  • The Return On Assets of BTMD (25.13%) is better than 98.44% of its industry peers.
  • The Return On Invested Capital of BTMD (44.85%) is better than 99.48% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for BTMD is significantly above the industry average of 12.98%.
  • The 3 year average ROIC (32.37%) for BTMD is below the current ROIC(44.85%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 25.13%
ROE N/A
ROIC 44.85%
ROA(3y)9.95%
ROA(5y)17.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)32.37%
ROIC(5y)N/A
BTMD Yearly ROA, ROE, ROICBTMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 200 400 600

1.3 Margins

  • BTMD has a Profit Margin of 14.07%. This is amongst the best in the industry. BTMD outperforms 86.98% of its industry peers.
  • In the last couple of years the Profit Margin of BTMD has declined.
  • BTMD has a Operating Margin of 18.50%. This is amongst the best in the industry. BTMD outperforms 86.46% of its industry peers.
  • BTMD's Operating Margin has declined in the last couple of years.
  • With a decent Gross Margin value of 71.46%, BTMD is doing good in the industry, outperforming 79.17% of the companies in the same industry.
  • BTMD's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 18.5%
PM (TTM) 14.07%
GM 71.46%
OM growth 3YN/A
OM growth 5Y-7.47%
PM growth 3YN/A
PM growth 5Y-10.89%
GM growth 3Y2.22%
GM growth 5Y3.08%
BTMD Yearly Profit, Operating, Gross MarginsBTMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

4

2. BTMD Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BTMD is creating value.
  • The number of shares outstanding for BTMD has been increased compared to 1 year ago.
  • BTMD has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for BTMD has been reduced compared to a year ago.
BTMD Yearly Shares OutstandingBTMD Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 10M 20M 30M
BTMD Yearly Total Debt VS Total AssetsBTMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • An Altman-Z score of 2.54 indicates that BTMD is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • The Altman-Z score of BTMD (2.54) is better than 66.67% of its industry peers.
  • BTMD has a debt to FCF ratio of 4.43. This is a neutral value as BTMD would need 4.43 years to pay back of all of its debts.
  • BTMD has a Debt to FCF ratio of 4.43. This is amongst the best in the industry. BTMD outperforms 84.38% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.43
Altman-Z 2.54
ROIC/WACC5.9
WACC7.6%
BTMD Yearly LT Debt VS Equity VS FCFBTMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M

2.3 Liquidity

  • A Current Ratio of 1.22 indicates that BTMD should not have too much problems paying its short term obligations.
  • The Current ratio of BTMD (1.22) is worse than 77.60% of its industry peers.
  • BTMD has a Quick Ratio of 1.22. This is a bad value and indicates that BTMD is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of BTMD (0.79) is worse than 82.29% of its industry peers.
Industry RankSector Rank
Current Ratio 1.22
Quick Ratio 0.79
BTMD Yearly Current Assets VS Current LiabilitesBTMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

6

3. BTMD Growth Analysis

3.1 Past

  • BTMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 277.27%, which is quite impressive.
  • The earnings per share for BTMD have been decreasing by -26.76% on average. This is quite bad
  • BTMD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -21.22%.
  • The Revenue has been growing by 10.51% on average over the past years. This is quite good.
EPS 1Y (TTM)277.27%
EPS 3YN/A
EPS 5Y-26.76%
EPS Q2Q%-40%
Revenue 1Y (TTM)-21.22%
Revenue growth 3Y5.22%
Revenue growth 5Y10.51%
Sales Q2Q%-6.87%

3.2 Future

  • BTMD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.65% yearly.
  • BTMD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.86% yearly.
EPS Next Y-69.28%
EPS Next 2Y-41.34%
EPS Next 3Y11.89%
EPS Next 5Y9.65%
Revenue Next Year2.37%
Revenue Next 2Y5.39%
Revenue Next 3Y10.42%
Revenue Next 5Y8.86%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
BTMD Yearly Revenue VS EstimatesBTMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
BTMD Yearly EPS VS EstimatesBTMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 1 1.5

8

4. BTMD Valuation Analysis

4.1 Price/Earnings Ratio

  • BTMD is valuated cheaply with a Price/Earnings ratio of 1.67.
  • Compared to the rest of the industry, the Price/Earnings ratio of BTMD indicates a rather cheap valuation: BTMD is cheaper than 98.96% of the companies listed in the same industry.
  • BTMD's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.96.
  • A Price/Forward Earnings ratio of 5.45 indicates a rather cheap valuation of BTMD.
  • 94.27% of the companies in the same industry are more expensive than BTMD, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 24.04. BTMD is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 1.67
Fwd PE 5.45
BTMD Price Earnings VS Forward Price EarningsBTMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 97.40% of the companies in the same industry are more expensive than BTMD, based on the Enterprise Value to EBITDA ratio.
  • BTMD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BTMD is cheaper than 98.96% of the companies in the same industry.
Industry RankSector Rank
P/FCF 1.94
EV/EBITDA 3.98
BTMD Per share dataBTMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • The decent profitability rating of BTMD may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.34%
EPS Next 3Y11.89%

0

5. BTMD Dividend Analysis

5.1 Amount

  • No dividends for BTMD!.
Industry RankSector Rank
Dividend Yield 0%

BTMD Fundamentals: All Metrics, Ratios and Statistics

BIOTE CORP -A

NASDAQ:BTMD (3/17/2026, 9:30:01 AM)

1.39

+0 (+0.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-11
Earnings (Next)05-05
Inst Owners63.61%
Inst Owner Change0.4%
Ins Owners10.06%
Ins Owner Change0%
Market Cap54.97M
Revenue(TTM)192.22M
Net Income(TTM)27.05M
Analysts81.82
Price Target4.94 (255.4%)
Short Float %5.15%
Short Ratio7.82
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)189.9%
Min EPS beat(2)17.65%
Max EPS beat(2)362.15%
EPS beat(4)4
Avg EPS beat(4)254.13%
Min EPS beat(4)17.65%
Max EPS beat(4)458.07%
EPS beat(8)5
Avg EPS beat(8)90.98%
EPS beat(12)7
Avg EPS beat(12)15.74%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.53%
Min Revenue beat(2)-1.55%
Max Revenue beat(2)-1.5%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)1.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.59%
Revenue beat(12)4
Avg Revenue beat(12)-1.42%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.91%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.87%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 1.67
Fwd PE 5.45
P/S 0.29
P/FCF 1.94
P/OCF 1.56
P/B N/A
P/tB N/A
EV/EBITDA 3.98
EPS(TTM)0.83
EY59.71%
EPS(NY)0.26
Fwd EY18.35%
FCF(TTM)0.72
FCFY51.53%
OCF(TTM)0.89
OCFY64.02%
SpS4.86
BVpS-1.48
TBVpS-1.85
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 25.13%
ROE N/A
ROCE 56.77%
ROIC 44.85%
ROICexc 72.95%
ROICexgc 117.64%
OM 18.5%
PM (TTM) 14.07%
GM 71.46%
FCFM 14.74%
ROA(3y)9.95%
ROA(5y)17.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)32.37%
ROIC(5y)N/A
ROICexc(3y)67.85%
ROICexc(5y)N/A
ROICexgc(3y)109.57%
ROICexgc(5y)N/A
ROCE(3y)40.97%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-44.74%
ROICexc growth 3YN/A
ROICexc growth 5Y-35.99%
OM growth 3YN/A
OM growth 5Y-7.47%
PM growth 3YN/A
PM growth 5Y-10.89%
GM growth 3Y2.22%
GM growth 5Y3.08%
F-Score7
Asset Turnover1.79
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.43
Debt/EBITDA 2.57
Cap/Depr 187.03%
Cap/Sales 3.57%
Interest Coverage 4.51
Cash Conversion 89.73%
Profit Quality 104.75%
Current Ratio 1.22
Quick Ratio 0.79
Altman-Z 2.54
F-Score7
WACC7.6%
ROIC/WACC5.9
Cap/Depr(3y)157.42%
Cap/Depr(5y)165.61%
Cap/Sales(3y)2.85%
Cap/Sales(5y)2.48%
Profit Quality(3y)682.14%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)277.27%
EPS 3YN/A
EPS 5Y-26.76%
EPS Q2Q%-40%
EPS Next Y-69.28%
EPS Next 2Y-41.34%
EPS Next 3Y11.89%
EPS Next 5Y9.65%
Revenue 1Y (TTM)-21.22%
Revenue growth 3Y5.22%
Revenue growth 5Y10.51%
Sales Q2Q%-6.87%
Revenue Next Year2.37%
Revenue Next 2Y5.39%
Revenue Next 3Y10.42%
Revenue Next 5Y8.86%
EBIT growth 1Y-15.43%
EBIT growth 3YN/A
EBIT growth 5Y2.26%
EBIT Next Year51.43%
EBIT Next 3Y25.51%
EBIT Next 5Y17.45%
FCF growth 1Y-26.01%
FCF growth 3YN/A
FCF growth 5Y2.5%
OCF growth 1Y-22.21%
OCF growth 3YN/A
OCF growth 5Y5.89%

BIOTE CORP -A / BTMD Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BIOTE CORP -A?

ChartMill assigns a fundamental rating of 6 / 10 to BTMD.


Can you provide the valuation status for BIOTE CORP -A?

ChartMill assigns a valuation rating of 8 / 10 to BIOTE CORP -A (BTMD). This can be considered as Undervalued.


Can you provide the profitability details for BIOTE CORP -A?

BIOTE CORP -A (BTMD) has a profitability rating of 7 / 10.


How financially healthy is BIOTE CORP -A?

The financial health rating of BIOTE CORP -A (BTMD) is 4 / 10.


How sustainable is the dividend of BIOTE CORP -A (BTMD) stock?

The dividend rating of BIOTE CORP -A (BTMD) is 0 / 10 and the dividend payout ratio is 0%.